Journal
FRONTIERS IN PHARMACOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2021.741413
Keywords
MLL-rearrangements; leukemia; drug repurposing; AML; ALL
Categories
Funding
- MRC [MR/S021000/1]
- GOSH Childrens Charity [W1003, V1305, V2617, V4819]
- NIHR Great Ormond Street Hospital Biomedical Research Centre
- MRC [MR/S021000/1] Funding Source: UKRI
Ask authors/readers for more resources
The high failure rates of treating acute leukemia with MLL gene rearrangements emphasize the need for novel therapeutic approaches. Drug repurposing provides valuable opportunities to quickly and effectively identify treatments for MLL-rearranged leukemia, with common oncogenic pathways potentially applicable to various types of MLL-rearranged leukemia.
The treatment failure rates of acute leukemia with rearrangements of the Mixed Lineage Leukemia (MLL) gene highlight the need for novel therapeutic approaches. Taking into consideration the limitations of the current therapies and the advantages of novel strategies for drug discovery, drug repurposing offers valuable opportunities to identify treatments and develop therapeutic approaches quickly and effectively for acute leukemia with MLL-rearrangements. These approaches are complimentary to de novo drug discovery and have taken advantage of increased knowledge of the mechanistic basis of MLL-fusion protein complex function as well as refined drug repurposing screens. Despite the vast number of different leukemia associated MLL-rearrangements, the existence of common core oncogenic pathways holds the promise that many such therapies will be broadly applicable to MLL-rearranged leukemia as a whole.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available